Xin Lang Cai Jing·2025-12-02 04:06Core Viewpoint - The news highlights the recent trading activity and financial performance of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, indicating a stable growth trajectory and significant trading volume in the stock market. Group 1: Trading Activity - On December 1, Baiyunshan's stock rose by 0.35% with a trading volume of 418 million yuan [1] - The financing buy-in amount for Baiyunshan on the same day was 37.50 million yuan, while the financing repayment was 19.72 million yuan, resulting in a net financing buy-in of 17.78 million yuan [1] - As of December 1, the total financing and securities lending balance for Baiyunshan was 922 million yuan, with the financing balance accounting for 2.53% of the circulating market value, indicating a high level compared to the past year [1] Group 2: Company Overview - Guangzhou Baiyunshan Pharmaceutical Holdings Company was established on September 1, 1997, and listed on February 6, 2001, with its main business involving the research, development, manufacturing, and sales of traditional Chinese and Western medicines, chemical raw materials, and health products [2] - The revenue composition of Baiyunshan includes 69.32% from large commercial operations, 16.79% from health products, and 12.53% from traditional Chinese medicine [2] - For the period from January to September 2025, Baiyunshan reported a revenue of 61.61 billion yuan, reflecting a year-on-year growth of 4.31%, and a net profit attributable to shareholders of 3.31 billion yuan, with a growth of 4.78% [2] Group 3: Dividend and Shareholding - Baiyunshan has distributed a total of 10.91 billion yuan in dividends since its A-share listing, with 4.36 billion yuan distributed over the past three years [3] - As of September 30, 2025, the top ten circulating shareholders included China Securities Finance Corporation, holding 47.28 million shares, while Hong Kong Central Clearing Limited reduced its holdings by 20.44 million shares [3] - Other notable shareholders include Huatai-PB CSI 300 ETF and E Fund CSI 300 Medical ETF, both of which saw a decrease in their holdings compared to the previous period [3]